Germline Testing News Today

/PRNewswire/ -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and...

Dr Noor Abuhadra discusses the various first-line treatment options for metastatic TNBC, highlighting the importance of PDL1 expression for immunotherapy and germline testing for targeted therapies like PARP inhibitors. Patient Shay Elkins shares her treatment journey, from her initial chemo and immunotherapy to surgical intervention, emphasizing the importance of a collaborative approach with her healthcare team and the supportive role of nursing staff.

This new data indicated a necessity for clinical strategies made to handle unintentional pathogenic or likely pathogenic germline variants seen in tumor-only next-generation sequencing.

Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical...

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, discusses testing guidance for identifying Lynch syndrome.

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.